You just read:

Affinium Pharmaceuticals, Ltd., Announces First Patient Dosed With Oral AFN-1252 in a Phase 2 Clinical Trial for Acute Bacterial Skin & Skin Structure Infections

News provided by

Affinium Pharmaceuticals

01 Feb, 2012, 18:19 GMT